with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. \[[PubMed: 19717846](https://pubmed.ncbi.nlm.nih.gov/19717846)\] 42. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24;352(12):1179-89. \[[PubMed: 15758000](https://pubmed.ncbi.nlm.nih.gov/15758000)\] 43. Braun M, Kassop D. Acute Coronary Syndrome: Management. FP Essent. 2020 Mar;490:20-28. \[[PubMed: 32150365](https://pubmed.ncbi.nlm.nih.gov/32150365)\] 44. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O., ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 01;41(1):111-188. \[[PubMed: 31504418](https://pubmed.ncbi.nlm.nih.gov/31504418)\] 45. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, Atar D, Otterstad JE. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 01;5(1):12-20. \[[PMC free article: PMC6321955](/pmc/articles/PMC6321955/)\] \[[PubMed: 30192930](https://pubmed.ncbi.nlm.nih.gov/30192930)\] 46. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001 May 05;357(9266):1385-90. \[[PubMed: 11356434](https://pubmed.ncbi.nlm.nih.gov/11356434)\] 47. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998 Jun 09;97(22):2202-12. \[[PubMed: 9631869](https://pubmed.ncbi.nlm.nih.gov/9631869)\] 48. Heart Outcomes Prevention Evaluation Study Investigators. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53. \[[PubMed: 10639539](https://pubmed.ncbi.nlm.nih.gov/10639539)\] 49. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020 Dec;17(12):761-772. \[[PubMed: 32665641](https://pubmed.ncbi.nlm.nih.gov/32665641)\] 50. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS., DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. \[[PubMed: 30415602](https://pubmed.ncbi.nlm.nih.gov/30415602)\] 51. Nadir M, Malik J. Should Men Also Fear Strong Positive Emotions? JACC Heart Fail. 2022 Aug;10(8):601. \[[PubMed: